PT - JOURNAL ARTICLE AU - Sylivia Nalubega AU - Karen Cox AU - Henry Mugerwa AU - Catrin Evans TI - Facilitated transition in HIV drug trial closure: a conceptual model for HIV post-trial care AID - 10.1101/2020.11.14.20231712 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.14.20231712 4099 - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231712.short 4100 - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231712.full AB - Within the HIV clinical trial field, there are gaps in existing ethical regulations in relation to post-trial care. There is need to develop post-trial care guidelines that are flexible and sensitive to local contexts and to the specific needs of different groups of participants, particularly in low income contexts. Evidence regarding HIV trial closure and post-trial care is required to underpin the development of appropriate policies in this area. This article reports research from Uganda that develops a new model of ‘Facilitated Transition’ to conceptualize the transition process of HIV positive trial participants from ‘research’ to ‘usual care’ health facilities after trial conclusion. This was a qualitative grounded theory study that included 21 adult HIV positive post-trial participants and 22 research staff, undertaken between October 2014 and August 2015. The findings showed that trial closure is a complex process for HIV positive participants which includes three phases: the pre-closure, trial-closure, and post-trial phases. The model highlights a range of different needs of research participants and suggests specific and person-centred interventions that can be delivered at different phases with the aim of improving health outcomes and experiences for trial participants in low income settings during trial closure. Further research needs to be done to verify the model in other contexts and for other conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The Ph.D programme under which the study was undertaken was sponsored by the Vice-Chancellors Scholarship for Research Excellence (International) and the University of Nottingham, United Kingdom.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was received from the University of Nottingham, UK and The AIDS Support Organization (TASO) Uganda, Research Ethics Committee (REC). The study was registered with the Uganda National Council for Science and Technology (UNCST), as SS3608. Permission to conduct the research was granted by the respective research institutions, and written informed consent was received from all respondents.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript can be accessed with permission from the corresponding author.